Abstract:The treatment options available for prostate cancer are limited because of its resistance to therapeutic agents. Thus, a better understanding of the underlying mechanisms of the resistance of prostate cancer will facilitate the discovery of more efficient treatment protocols. Human phosphatidylethanolamine-binding protein 4 (hPEBP4) is recently identified by us as an anti-apoptotic molecule and a potential candidate target for breast cancer treatment. Here we found the expression levels of hPEBP4 were positively correlated with the severity of clinical prostate cancer. Furthermore, hPEBP4 was not expressed in TRAIL-sensitive DU145 prostate cancer cells, but was highly expressed in TRAIL-resistant LNCaP cells, which show highly activated Akt. Interestingly, hPEBP4 overexpression in TRAILsensitive DU145 cells promoted Akt activation but inhibited ERK1/2 activation. The hPEBP4-overexpressing DU145 cells became resistant to TRAIL-induced apoptosis consequently, which could be reversed by PI3K inhibitors. In contrast, silencing of hPEBP4 in TRAIL-resistant LNCaP cells inhibited Akt activation but increased ERK1/2 activation, resulting in their sensitivity to TRAIL-induced apoptosis that was restored by the MEK1 inhibitor. Therefore, hPEBP4 expression in prostate cancer can activate Akt and deactivate ERK1/2 signaling, leading to TRAIL resistance. We also demonstrated that hPEBP4-mediated resistance to TRAIL-induced apoptosis occurred downstream of caspase-8 and at the level of BID cleavage via the regulation of Akt and ERK pathways, and that hPEBP4-regulated ERK deactivation was upstream of Akt activation in prostate cancer cells. Considering that hPEBP4 confers cellular resistance to TRAIL-induced apoptosis and is abundantly expressed in poorly differentiated prostate cancer, silencing of hPEBP4 suggests a promising approach for prostate cancer treatment. Prostate cancer is the most common malignancy and one of the leading causes of cancer mortality in men. The development of human prostate cancer has been viewed as amultistage process, involving the onset as small latent carcinoma of low histological grade to large metastatic lesion of higher grade. Unfortunately, chemotherapy and radiation therapy are not effective for prostate cancer patients. Therefore, a better understanding of molecular mechanisms for the resistance of prostate cancer cells to therapeutic agents will be useful to explore more efficient treatment protocols. Multiple signaling pathways govern the progression of prostate cancer, and the two most significant and well investigated pathways are the phosphatidylinositol 3-kinase (PI3K)3/Akt and MAPK pathways (1, 2).ThePI3K/Aktpathwaymediatessurvivalsignalsinandrogendependent and -independent prostate tumor cell lines, and controls the progression of prostate cancer to an androgenindependent state (1). The activation of ERK1/2 is detectable in premalignant lesions and/or early stage cancers; hence, it may play a role in the pathogenesis or early progression of prostate cancer (3, 4). It has been shown that activation of Akt and inactivation of ERK in high Gleason-grade prostate cancer, and importantly, increased Akt activation, alone or together with decreased ERK activation, is an excellent predictor of poor clinical outcome in prostate cancer (6). Therefore, overactivation of the Akt pathway is regarded as one of the reasons for resistance of prostate cancer to therapeutic agents, and targeting to inhibit Akt activationmay be beneficial in order to increase the therapeutic efficacy of human prostate cancer. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) acts through the pro-apoptotic TRAIL-R1/DR4 and TRAIL-R2/DR5 receptors, which leads to the cleavage and activation of caspase-8, resulting in BID cleavage, a Bcl-2 inhibitory protein, and triggering mitochondrial depolarization in tumor cells (7–9). TRAIL is currently being tested in clinical trials as an anticancer agent for barely detectable systemic cytotoxic effects. Recent studies have shown that Akt and ERK are all important regulators of TRAIL sensitivity in many cancers including prostate cancer (10–12). Akt phosphorylates specific * This work was supported in part by Grants from the National Natural Science Foundation of China (30600747, 30121002, 30490240), TsinghuaYue-Yuen Medical Sciences Fund (202400.005-02), the National Key Basic Research Program of China (2001CB510002), and the National High Biotechnology Development Program of China (2002BA711A01). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 These authors contributed equally to this work. 2 To whom correspondence should be addressed: Inst. of Immunology and National Key Laboratory of Medical Immunology, Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, China. Fax: 86-21-65382502; E-mail: caoxt@public3.sta.net.cn. 3 The abbreviations used are: PI3K, phosphatidylinositol 3-kinase; Akt/PKB, protein kinase B; ERK, extracellular signal-regulated kinase; PEBP, phosphatidylethanolamine-binding protein; PI, propidium iodide; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; TNF, tumor necrosis factor; FACS, fluorescent-activated signal sorting; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase. THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 282, NO. 7, pp. 4943–4950, February 16, 2007 © 2007 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.

The role of PI3K/AKT/c‐FLIP in trail‐induced apoptosis in colon cancer

Study on the Regulation of PKCα on Apoptosis Inhibited by FGF‐2 in Small Cell Lung Cancer

c-FOS promotes trail-induced apoptosis by repressing c-FLIP(L)

Overcoming acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand by Bcl-XL small interfering RNA in human colon cancer

Resists TRAIL-induced Apoptosis of Human Prostate Cancer Cells by Activating Akt and Deactivating ERK 1 / 2 Pathways *

Inhibition of Phospholipased2 Increases Hypoxia-Induced Human Colon Cancer Cell Apoptosis Through Inactivating of the PI3K/AKT Signaling Pathway

A phase Ib study of the PI3K delta inhibitor linperlisib in patients with advanced solid tumors.

C-Flip Degradation Mediates Sensitization of Pancreatic Cancer Cells to TRAIL-induced Apoptosis by the Histone Deacetylase Inhibitor LBH589.

Differential Proteomics Research of Camptothecin Analog NSC606985 Inducing Apoptosis in U937 Cells: Phosphorylation of Three Kinds of Cytoskeleton Proteins

GSK3β/ITCH/c-FLIP Axis Counteracts TRAIL-induced Apoptosis in Human Lung Adenocarcinoma Cells

PKCα–GSK3β–NF-κB Signaling Pathway and the Possible Involvement of TRIM21 in TRAIL-induced Apoptosis

Abstract 203: the Histone Deacetylase Inhibitor LBH589 Sensitizes Pancreatic Cancer Cells to TRAIL-induced Apoptosis Through Induction of C-Flip Degradation

IL-8 and PI3K pathway influence the susceptibility of TRAIL-sensitive colorectal cancer cells to TRAIL-induced cell death

Hnrnpk Inhibits GSK3β Ser9 Phosphorylation, Thereby Stabilizing C-Flip and Contributes to TRAIL Resistance in H1299 Lung Adenocarcinoma Cells

[Correlation of PI3K-Akt Signal Pathway to Apoptosis of Tumor Cells].

Depletion of Pi3k P85 Alpha Induces Cell Cycle Arrest and Apoptosis in Colorectal Cancer Cells

Relationship between c-FLIP protein and drug resistance of ovarian cancer cells to TRAIL-induced apoptosis

Phosphatidylinositol 3-kinase CB association with preoperative radiotherapy response in rectal adenocarcinoma.

Effect of Insulin-Like Growth Factor-ⅰ(Igf-ⅰ)on Apoptosis of Colon Cancer Cell and Its Mechanism

A tumor down‐regulated gene NOR1 induced by hypoxia promote apoptosis in Hela cells

Over-expression of c-FLIP confers the resistance to TRAIL-induced apoptosis on gallbladder carcinoma.